Article

Silicone hydrogel daily disposable contact available

A new silicone hydrogel daily disposable contact lens (1-Day Acuvue TruEye, Vistakon) is now available in the United States, after having been cleared by the FDA in June.

Orlando, FL-A new silicone hydrogel daily disposable contact lens (1-Day Acuvue TruEye, Vistakon) is now available in the United States, after having been cleared by the FDA in June.

It is the first and only such contact lens available in the United States, according to the manufacturer.

The contact lens combines narafilcon B, which is a silicone hydrogel material, and proprietary technology (Hydraclear 1). It also offers the highest level of ultraviolet radiation protection in a contact lens, according to the company.

An ongoing 1-year, 94-subject, randomized, investigator-masked, parallel-group study compared eyes of patients wearing the new contact lens with eyes of patients who never have worn contact lenses. After the contact lens-wearing patients had worn the silicone hydrogel daily disposable lenses for 1 month, the contact lens was shown to have no significant effect on the ocular surface of the patients’ eyes compared with the ocular surface of the eyes of the non-contact lens wearers across five of six contact lens-related measures associated with eye health. In addition, the new contact lens was shown to provide high levels of comfort from morning to night, comparable with wearing no contact lens, according to the company.

“The data suggest that [the lens] can help maintain ocular health with the near ‘no-lens’ experience and keep the lens-wearing eye looking white and healthy, while also providing consistent comfort throughout the day,” said Colleen Riley, OD, MS, FAAO, vice president of professional development at Vistakon.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.